VISEN Pharmaceuticals (2561) AI Stock Analysis

• Market Cap: HK$4.33B
• Dividend Yield: N/A
• Average Volume (3M): 43.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.61
• Shares Outstanding: 113,926,865
• 10 Day Avg. Volume: 55,350
• 30 Day Avg. Volume: 43,783
• PEG Ratio: 1.23
• Price to Book (P/B): 25.08
• Price to Sales (P/S): 2178.79
• P/FCF Ratio: -42.92
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: HK$37.00 ▼(-10.11% Downside)

The overall stock score is primarily influenced by financial performance and technical analysis. While there is positive revenue growth, significant profitability and cash flow challenges persist. The technical indicators suggest bearish momentum, with the stock being oversold. Valuation is difficult to assess due to the lack of key metrics.

VISEN Pharmaceuticals Business Overview & Revenue Model

Company Description

VISEN Pharmaceuticals (2561) is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments for serious medical conditions. Operating primarily in the pharmaceutical sector, VISEN specializes in developing therapies for oncology and autoimmune diseases, aiming to address unmet medical needs with its advanced drug candidates. The company leverages cutting-edge technology and scientific expertise to create novel drug formulations that improve patient outcomes.

How the Company Makes Money

VISEN Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications for various diseases. The company’s revenue model is based on direct sales to healthcare providers, hospitals, and pharmacies, as well as potential licensing agreements for its drug candidates. Key revenue streams include product sales, royalties from licensing deals, and collaborations with other pharmaceutical companies for co-development and commercialization of drugs. Significant partnerships with research institutions and healthcare organizations also enhance its capabilities and market reach, contributing to its overall earnings.

VISEN Pharmaceuticals Financial Statement Overview

Summary

VISEN Pharmaceuticals is experiencing positive revenue growth but faces significant profitability challenges. The balance sheet is strong with low leverage, but operational inefficiencies persist. Cash flow improvements are noted, yet cash outflows remain a concern.

Income Statement

VISEN Pharmaceuticals has shown significant revenue growth, moving from negative to positive revenue figures. However, the company is still experiencing substantial losses, as indicated by negative net profit and EBIT margins. The gross profit margin is positive, but the overall profitability remains a concern due to high operating losses.

Balance Sheet

The company maintains a low debt-to-equity ratio, indicating minimal leverage, which is a positive aspect. However, the return on equity is negative, reflecting ongoing losses and inefficiencies in generating returns from equity. The equity ratio is stable, suggesting a solid capital structure despite operational challenges.

Cash Flow

VISEN Pharmaceuticals has improved its free cash flow, but it remains negative, indicating cash outflows. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is closely aligned with net income, albeit both being negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	-1.81M	2.78M	-1.67M	-2.30M
Gross Profit	-1.81M	2.78M	-1.67M	-2.30M
EBITDA	-160.03M	-177.62M	-242.26M	-280.95M
Net Income	-170.77M	-182.24M	-249.57M	-288.97M
Balance Sheet
Total Assets	893.36M	293.82M	443.80M	741.27M
Cash, Cash Equivalents and Short-Term Investments	805.91M	203.59M	347.78M	626.46M
Total Debt	1.20M	2.36M	3.65M	6.00M
Total Liabilities	37.81M	52.55M	52.92M	88.67M
Stockholders Equity	855.55M	241.28M	390.88M	652.61M
Cash Flow
Free Cash Flow	-147.14M	-140.97M	-271.83M	-248.31M
Operating Cash Flow	-147.14M	-140.86M	-271.31M	-246.55M
Investing Cash Flow	9.24M	-117.00K	-520.00K	-1.77M
Financing Cash Flow	700.98M	-3.09M	-6.95M	-7.95M

VISEN Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3886	―	HK$1.96B	―	-4.66%	0.44%	-0.55%	45.36%
1875	―	HK$1.54B	189.52	0.99%	―	9.41%	-32.69%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3681	―	HK$2.43B	―	-55.33%	―	-100.00%	30.68%
2561	―	HK$4.33B	―	―	―	―	―
2216	―	HK$1.43B	-11.10	-8.93%	―	-30.60%	28.61%

VISEN Pharmaceuticals Corporate Events

VISEN Pharmaceuticals Appoints New Chief Financial Officer

VISEN Pharmaceuticals has appointed Mr. Lu Ying as its new Chief Financial Officer, effective October 13, 2025. Mr. Lu brings over 19 years of financial management experience, having previously served in key financial roles at VivaVision Biotech Limited, Allergan Information Consulting, and Bayer A.G. His extensive background in corporate finance, investor relations, and strategic planning is expected to enhance VISEN Pharmaceuticals’ financial operations and strengthen its industry positioning.

The most recent analyst rating on (HK:2561) stock is a Hold with a HK$41.00 price target. To see the full list of analyst forecasts on VISEN Pharmaceuticals stock, see the HK:2561 Stock Forecast page.

VISEN Pharmaceuticals Amends Supply Agreement with Ascendis Europe

VISEN Pharmaceuticals has announced an amendment to its Commercial Supply Framework Agreement with Ascendis Europe, allowing a broader range of entities within the Ascendis Group to supply products. This amendment aims to optimize internal resource allocation and provide greater flexibility for both VISEN and Ascendis, enhancing their collaborative efforts.

VISEN Pharmaceuticals Announces Board Composition and Committee Roles

VISEN Pharmaceuticals has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board also oversees three committees: the Audit Committee, Remuneration Committee, and Nomination Committee, with specific directors assigned as chairpersons and members. This announcement clarifies the governance structure and roles within the company, potentially impacting its strategic direction and stakeholder engagement.

VISEN Pharmaceuticals Reports Interim Results and Advances Core Product

VISEN Pharmaceuticals announced their interim results for the first half of 2025, highlighting a significant increase in research and development costs and administrative expenses, leading to a larger loss compared to the previous year. Despite the financial losses, the company made progress in its core product, Lonapegsomatropin, by completing regulatory steps and strengthening supply arrangements. They also entered into a strategic collaboration to enhance commercial coverage in China, indicating a focused effort to improve market positioning and product uptake.

VISEN Pharmaceuticals Schedules Board Meeting for Interim Results Review

VISEN Pharmaceuticals has announced that its board of directors will convene on August 27, 2025, to review and approve the interim financial results for the first half of the year ending June 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.